Abstract
The study was designed to determine whether the number of CD34+/CD33− cells given at autologous peripheral blood stem cell (PBSC) rescue after intensive therapy for cancer was a better predictor of platelet engraftment than the total number of CD34+ cells infused. Comparison between the total number of CD34+ cells/kg infused with the number of CD34+/CD33− cells/kg infused showed that, generally, 2 × 106 total CD34+ cells contained 1.38 × 106 CD34+/CD33− cells. There was poor correlation between the number of CD34+/CD33− and CD34+/ CD33+ cells in the graft (r = 0.332). Engraftment times for platelets and neutrophils were evaluated in 68 patients. There was no significant difference between the times for platelets to reach >25 × 109/l or neutrophils to reach >0.5 × 109/l among patients who received > or <2 × 106 total CD34+ cells or > or <1.38 × 106 CD34+/CD33− cells although the latter was consistently the better predictor. Platelet recovery to >50 × 109/l and >100 × 109/l was delayed significantly in patients who received <1.38 × 106 CD34+/CD33−/kg infused (P < 0.02 and P < 0.05, respectively). The number of cd34+/ CD33− cells/kg infused was a stronger predictor of platelet recovery than the total number of CD34+ cells infused (P < 0.05 for platelets >50 or >100 × 109/l). Although platelet recovery was delayed significantly in patients who had <4 × 104 granulocyte–macrophage colony-forming units (CFU-GM)/kg infused, the time delay between receipt of PBSCs and availability of the colony counts limits the use of this assay to patients who do not require stem cells to be given immediately. Our data suggest that the number of CD34+/CD33− cells given at PBSC rescue provide information about the quality of the graft necessary for long-term platelet engraftment. However, since the percentage of CD34+/CD33− cells shows considerable inter-patient variation, measurement of this cell population may be important in patients who experience poor stem cell mobilization or when a target dose of 2 × 106 total CD34+ cells/kg is not achieved.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Millar, B., Millar, J., Shepherd, V. et al. The importance of CD34+/CD33− cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. Bone Marrow Transplant 22, 469–475 (1998). https://doi.org/10.1038/sj.bmt.1701368
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701368
Keywords
This article is cited by
-
Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments
Annals of Hematology (2023)
-
Optimal timing of G-CSF administration for effective autologous stem cell collection
Bone Marrow Transplantation (2011)
-
Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation
Bone Marrow Transplantation (2007)
-
Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma
Bone Marrow Transplantation (2002)
-
The CD34+90+ cell dose does not predict early engraftment of autologous blood stem cells as well as the total CD34+ cell dose
Bone Marrow Transplantation (2000)